|
Exploring Advances in the Early Diagnosis and Treatment of Alzheimer Disease
STATEMENT OF NEED
Alzheimer disease, the most common form of dementia among older adults, is a slowly progressive neurogenerative disease that affects approximately 6 million Americans aged 65 and older (Rajan et al, 2021). Symptoms of Alzheimer disease include memory loss, confusion, impulsive behavior, difficulty with language, mood and personality changes, hallucinations, and increased anxiety or aggression, with severe symptoms such as physical decline, difficulty swallowing, and inabil... |
|
Improving Alzheimer’s Disease Management: Updates on Patient Diagnosis and Treatment
The face of mild cognitive impairment (MCI) and Alzheimer’s disease (AD) diagnosis and management is rapidly changing. A growing understanding of AD pathophysiology has shaped research of targeted therapies and helped clinicians better understand the causes of the disease and the utility of biomarkers. Though cognitive testing is still a critical component of diagnosis, it no longer stands alone. Biomarkers are increasingly incorporated into practice to aid in diagnosis of MCI and AD and to ... |
|
Top 10 Questions on Biomarkers in Early Alzheimer’s Disease: Improving Diagnosis and Use of Targeted Therapies
The past several years have seen numerous advances in Alzheimer’s disease (AD) diagnosis and management. Most recently, approval of antiamyloid monoclonal antibodies has revolutionized AD management and has required that patients have amyloid burden verified prior to initiating treatment. Biomarkers, whether obtained from cerebrospinal fluid (CSF) or positron emission tomography (PET) scans, are critical to the early diagnosis of AD and its subsequent management. Plasma biomarkers are an eme... |